IGLVI-38: A Potential Drug Target and Biomarker (G28768)

Target Name: IGLVI-38

NCBI ID: G28768

IGLVI-38

Other Name(s): IGLV(I)-38 | IGLVI38 | immunoglobulin lambda variable (I)-38 (pseudogene) | Immunoglobulin lambda variable (I)-38 (pseudogene) | V1-12P

IGLVI-38: A Potential Drug Target and Biomarker

IGLVI-38 (IGLV(I)-38) is a protein that is expressed in various tissues of the human body, including the brain, heart, kidneys, and intestines. It is a member of the intergenital nephritis (INGN) family, which includes several proteins that are involved in the regulation of inflammation and autoimmune diseases. In this article, we will discuss the potential implications of IGLVI-38 as a drug target and biomarker.

Potential Drug Target

IGLVI-38 has been shown to play a key role in the development and progression of several autoimmune diseases, including autoimmune uveitis (AU), a type of eye disease that can cause blindness. In these diseases, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. IGLVI-38 has been shown to contribute to the development and progression of AU by regulating the activity of T cells, which are a key immune cell involved in the development of autoimmune diseases.

In addition to its role in autoimmune diseases, IGLVI-38 has also been shown to contribute to the development of other diseases, including inflammatory bowel disease (IBD) and multiple sclerosis (MS). IGLVI-38 has been shown to regulate the activity of immune cells in these diseases, and to play a role in the development of their symptoms.

Potential Biomarker

IGLVI-38 has also been shown to be a potential biomarker for several diseases, including AU, IBD, and MS. In these diseases, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. IGLVI-38 has been shown to contribute to the development and progression of these diseases by regulating the activity of immune cells, which are a key part of the immune system.

IGLVI-38 has been shown to be involved in the regulation of T cell activity, which is a key part of the immune system. In diseases such as AU, IGLVI-38 has been shown to regulate the activity of T cells in a way that contributes to the development and progression of the disease.

In addition to its role in immune system regulation, IGLVI-38 has also been shown to contribute to the development and progression of other diseases, including MS. In MS, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. IGLVI-38 has been shown to contribute to the development and progression of MS by regulating the activity of immune cells in this disease.

Conclusion

IGLVI-38 is a protein that has been shown to play a key role in the development and progression of several autoimmune diseases, including AU, IBD, and MS. In these diseases, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. IGLVI-38 has been shown to regulate the activity of immune cells, which are a key part of the immune system, and to contribute to the development and progression of these diseases.

With its potential as a drug target and biomarker, IGLVI-38 is an promising target for future research and treatment of autoimmune diseases. Further studies are needed to fully understand the role of IGLVI-38 in these diseases and to develop effective treatments.

Protein Name: Immunoglobulin Lambda Variable (I)-38 (pseudogene)

The "IGLVI-38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVI-38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets